Kinfo
Aclaris Therapeutics, Inc. logo

Aclaris Therapeutics, Inc.

ACRSNASDAQHealthcare·US · USD
$5.51
+0.01 (+0.18%)
Prices as of July 14, 2026 · live

Price

Key statistics

Valuation
Market cap768.15M USD
Enterprise value675.89M USD
Trailing P/E-10.38
Forward P/E-6.73
PEG ratio-0.42
Price / sales93.14
Price / book5.42
Profitability
Gross margin10.42%
Operating margin-1111.82%
Profit margin6.93%
Return on assets-24.72%
Return on equity-48.42%
Income (TTM)
Revenue8.37M USD
Gross profit-55.91M USD
EBITDA-78.47M USD
Net income-69.66M USD
Diluted EPS-$0.56
Rev. growth (YoY)37.20%
Balance sheet
Total cash105.42M USD
Total debt1.99M USD
Debt / equity1.38
Current ratio4.03
Book value / share$1.03
Cash flow (TTM)
Operating cash flow-52.20M USD
Levered free cash flow-32.21M USD
Shares & price
Shares outstanding139.65M
Float113.14M
Held by institutions79.63%
Beta0.77
50-day MA$4.74
200-day MA$3.47
52-week high$5.85
52-week low$1.46
Dividends
Forward rate
$0.00
Yield
0.00%
Payout ratio
0.00%
Frequency
Unknown
Earnings (EPS)
DateEst.ActualSurprise2026-05-040.780.87+11.54%2026-03-110.570.51−10.53%2026-02-26-0.14-0.16−14.29%2026-01-170.380.34−10.53%
About Aclaris Therapeutics, Inc.

Aclaris Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases. It operates through two segments: Therapeutics, which identifies and advances innovative therapies to meet unmet needs in conditions such as atopic dermatitis, asthma, and alopecia areata, and Contract Research, which provides laboratory services. Key product candidates include ATI-2138, a potent and selective oral ITK/JAK3 inhibitor demonstrating efficacy in clinical trials for atopic dermatitis and preclinical hair regrowth in alopecia areata models; ATI-052, a bispecific anti-TSLP/IL-4Rα antibody advancing in Phase 1b proof-of-concept trials for atopic dermatitis and asthma with favorable safety, pharmacokinetics, and pharmacodynamics; bosakitug (ATI-045), an anti-TSLP monoclonal antibody in Phase 2 trials for moderate-to-severe atopic dermatitis; and others like zunsemetinib and lepzacitinib. Aclaris Therapeutics Inc. targets immune-inflammatory disorders lacking satisfactory treatments, contributing to advancements in immunology through its oral kinase inhibitors and biologics franchises. Founded in 2012 and headquartered in Wayne, Pennsylvania, it plays a role in the biotechnology sector by progressing multiple candidates through clinical development.

Sector
Healthcare
Industry
Biotechnology
CEO
Dr. Neal S. Walker D.O., M.D.
Employees
61
Headquarters
Wayne, PA, United States

Frequently asked questions about Aclaris Therapeutics, Inc.